The goal of this study was to elucidate the molecular mechanisms underlying how two TRPV4 gain-of-function mutations lead to strikingly distinct severities of skeletal dysplasias (i.e., moderate brachyolmia vs. lethal metatropic dysplasia). Here, TRPV4 is linked to brachyolmia.